Bisphosphonate use in patients undergoing dialysis

Consultant Pharmacist

Volumn 28, Issue 11, 2013, Pages 738-741

  Vouri, Scott Martin ^a,b   Blaszczyk, Amie Taggart ^c  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b Alexian Brothers Community Services PACE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Bisphosphonate; Chronic kidney disease; Dialysis; End stage kidney disease; Osteoporosis; Renal

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ARTICLE; BLOOD FLOW VELOCITY; BONE DENSITY; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIALYSIS MEMBRANE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG PROTEIN BINDING; FRACTURE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; KIDNEY CLEARANCE; MOLECULAR WEIGHT; OSTEOPOROSIS; RENAL REPLACEMENT THERAPY;

BISPHOSPHONATE; BMD = BONE MINERAL DENSITY; CHRONIC KIDNEY DISEASE; CKD = CHRONIC KIDNEY DISEASE; DIALYSIS; ECLCR = ESTIMATED CREATININE CLEARANCE; END-STAGE KIDNEY DISEASE; IV = INTRAVENOUS; KDIGO = KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES; KUF = ULTRAFILTRATION COEFFICIENT; OSTEOPOROSIS; PTH = PARATHYROID HORMONE; RANK = RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B; RENAL;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; KIDNEY FUNCTION TESTS; OSTEOPOROSIS; PREVALENCE; RENAL DIALYSIS; RISK;

EID: 84888592856     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2013.738     Document Type: Article

References (22)

1. Hamdy RC, Chestnut CH III, Gass ML et al. Review of treatment modalities for postmenopausal osteoporosis. South Med J 2005;98:1000-14.
2. Klawansky S, Komaroff E, Cavanaugh PF et al. Relationship between age, renal function, and bone mineral density in the US population. Osteoporosis Int 2003;14:570-6.
3. Fosamax (alendronate) package insert. Whitehouse Station, NJ: Merck & Co, Inc; January 2011.
4. Boniva (ibandronate) package insert. San Francisco, CA: Genetech USA, Inc; January 2011.
5. Actonel (risedronate) package insert. North Norwich, NY: Norwich Pharmaceuticals, Inc; January 2011.
6. Reclast (zoledronic acid) package insert. East Hanover, NJ: Norvartis Pharmaceutical Corporation; August 2011.
7. Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. The Oncologist 2005;10 Suppl 1:3-7.
8. Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dialysis 2007;20:186-90.
9. Esroy FF. Osteoporosis in the elderly with chronic kidney disease. Int Urol Neprhol 2007;39:321-31.
10. Block GA, Klassen PS, Lazurus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
11. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney diseasemineral and bone disorder (CKD-MBD). Kidney Int 2009;76 Suppl 113:S1-S130.
12. Morton AR. Bisphosphonates for the hypercalcemia of malignancy in end-stage renal disease. Semin Dialysis 1994;7:76-7.
13. Stevens LA, Coresh J, Greene T et al. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-83.
14. Ala-Houhala I, Saha H, Liukko-Sipi S et al. Pharmacokinetics of clodronate in haemodialysis patients. Nephrol Dial Transplant 1999;14:699-705.
15. Bergner R, Dill K, Boerner D et al. Elimination of intravenously administered ibandronate in patients on hemodialysis: a monocentre open study. Nephrol Dial Transplant 2002;17:1281-5.
16. Bailie GR, Mason NA. 2012 Drug and dialysis. Renal Pharmacy Consultants, LLC. Available at http://renalpharmacyconsultants.com/sitebuildercontent/ sitebuilderfiles/2012dialysisofdrugsbooklet.pdf.
17. Torregrosa JV, Moreno A, Mas M et al. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int 2003;63:S88-S90.
18. Prolia (denosumab) package insert. Thousand Oaks, CA: Amgen Manufacturing Limited; September 2012.
19. McCormick BB, Davis J, Burns KD. Severe hypocalcemia following denosumab infection in a hemodialysis patient. Am J Kidney Dis 2012;60:626-8.
20. Aredia (pamidronate) package insert. East Hanover, NJ: Norvartis Pharmaceutical Corporation; May 2012.
21. Skelid (tiludronate) package insert. Bridgewater, NJ: Sanofi-Aventis U. S. LLC; March 2010.
22. Didronel (etidronate) package insert. North Norwich, NY: OSG Norwich; May 2005.